siRNA作为高血压的潜在治疗策略
Srushti Tanna1, Gaurav Doshi1, Angel Godad1
1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V L M Road, Vile Parle (w), Mumbai, 400056, India.
European journal of pharmacology
|March 2, 2024
概括
使用小干扰RNA (siRNA) 的RNA干扰 (RNAi) 疗法,通过沉默特定的基因,为治疗高血压提供了一种新的方法. 这种分子工具准了参与血压调节的基因,为未来的高血压治疗带来了希望.
科学领域:
- 心血管医学 心血管医学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 高血压是一种主要的全球心血管疾病,其特点是血压升高.
- RNA干扰 (RNAi) 疗法为针对复杂疾病提供了一种新的分子策略.
- 小干扰RNA (siRNA) 为治疗干预提供了精确的基因调制.
研究的目的:
- 探索基于siRNA的高血压疗法的潜力.
- 识别和准涉及高血压分子机制的特定基因.
- 为了评估新型的治疗目标超出血管激素对血压调节.
主要方法:
- 利用siRNA选择性地准和下调特定的信使RNA (mRNA) 分子.
- 研究与高血压有关的基因的基因沉默策略.
- 分析尿素 (UMOD) 和高血压之间的遗传相关性.
主要成果:
- siRNA疗法可以使导致高血压的基因沉默,包括血管调和处理的基因.
- 一项临床试验正在进行中,该试验正在调查血管激素原siRNA (AGT siRNA).
- 乌罗莫杜林 (UMOD) 被确定为潜在的非AGT siRNA标,因为它在调节中的作用.
结论:
- siRNA疗法对高血压的预后,诊断和治疗具有重大前景.
- 针对UMOD提供了一条通过调节运输来调节血压的新途径.
- 基于siRNA的策略代表了在分子水平上管理高血压的突破性方法.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Antihypertensive Drugs: Vasodilators
519
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
519
Antihypertensive Drugs: Direct Renin Inhibitors
625
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
625
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
512
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
730
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
730


